---
schema_version: "secwatch.filing_event.v1"
accession: "0001453687-24-000084"
form_type: "8-K"
ticker: "RNAC"
cik: "0001453687"
company_name: "Cartesian Therapeutics, Inc."
filed_at: "2024-05-22T23:59:59+00:00"
generated_at: "2026-06-01T09:42:27.739384+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cartesian Therapeutics receives FDA RMAT designation for Descartes-08 in myasthenia gravis

## Summary
- FDA granted RMAT designation for Descartes-08, an autologous mRNA CAR-T therapy targeting BCMA for myasthenia gravis.
- RMAT designation provides fast track and breakthrough therapy benefits, enabling expedited FDA interactions and development.
- Topline data from Phase 2b randomized, double-blind, placebo-controlled trial of Descartes-08 in MG expected mid-2024.
- Descartes-08 previously received FDA Orphan Drug Designation for MG.
- Phase 2a data (Jan 2024) showed durable autoantibody depletion and clinically meaningful MG severity score improvements over 12 months.

## SEC filing metadata
- accession: 0001453687-24-000084
- form_type: 8-K
- ticker: RNAC
- cik: 0001453687
- company_name: Cartesian Therapeutics, Inc.
- filed_at: 2024-05-22T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453687/000145368724000084/0001453687-24-000084-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453687/000145368724000084/rnac-20240522.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001453687-24-000084
- JSON: https://secwatch.observer/filing/0001453687-24-000084.json
- Plain text: https://secwatch.observer/filing/0001453687-24-000084.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.